p16INK4a expression in cytology of ascites and response to chemotherapy in advanced ovarian cancer

International Journal of Cancer

Volumn 125, Issue 2, 2009, Pages 339-344

  Goto, Tomoko ^a   Takano, Masashi ^b   Hirata, Junko ^b   Kohno, Toshiyuki ^c   Ohtsuka, Shigenori ^c   Fujiwara, Keiichi ^a   Tsuda, Hitoshi ^b  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c Biomedical Laboratories   (Japan)

Author keywords

Chemotherapeutic response; Immunocytochemistry; Ovarian cancer; p16iNK4a; Prognosis

Indexed keywords

CARBOPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; ASCITES FLUID CYTOLOGY; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; CYTOREDUCTIVE SURGERY; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MUCINOUS CARCINOMA; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY ADENOCARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TREATMENT RESPONSE; WESTERN BLOTTING; ADULT; AGED; ASCITES; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASCITES; BLOTTING, WESTERN; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 67449091167     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24315     Document Type: Article

References (31)

1. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991;42:146-50.
2. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998;71:431-6.
3. Kayikçioglu F, Köse MF, Boran N, Caliçskan E, Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001;11:466-70.
4. Vergote I, de Wever I, Tjalma W, Van Gramberen M, Decloedt J, Van Dam P. Interval debulking surgery: an alternative for primary surgical debulking? Semin Surg Oncol 2000;19:49-53.
5. Onda T, Kamura T, Hirakawa T, Kuzuya K, Hatae M, Iwasaka T, Konishi I, Katsumata N, Fukuda H, Yoshikawa H. Feasibility study of neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group study JCOG0206 (Abstract 15020). J Clin Oncol ASCO Annu Meeting Proc 2006;24:15020.
6. Vergote I, Trope CG, Amant F, Kristensen GB, Sardi JE, Ehlen T, Johnson N, Verheijen RHM, Van der Burg MEL, Lacave AJ, Benedetti-Panici P, Kenter GG, et al. EORTC-GCG/NCIC-CTG randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA). Proceedings of 12th Biennial Meeting International Gynecologic Cancer Society, Bangkok, October 2008:1767.
7. Nam EJ, Kim YT. Alteration of cell-cycle regulation in epithelial ovarian cancer. Int J Gynecol Cancer 2008;18:1169-82.
8. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, 3rd, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
9. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6.
10. Ichikawa Y, Yoshida S, Koyama Y, Hirai M, Ishikawa T, Nishida M, Tsunoda H, Kubo T, Miwa M, Uchida K. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors. Int J Cancer 1996;69:466-70.
11. Dong Y, Walsh MD, McGuckin MA, Gabrielli BG, Cummings MC, Wright RG, Hurst T, Khoo SK, Parsons PG. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer 1997;74:57-63.
12. Kusume T, Tsuda H, Kawabata M, Inoue T, Umesaki N, Suzuki T, Yamamoto K. The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res 1999;5:4152-7.
13. Sui L, Dong Y, Ohno M, Goto M, Inohara T, Sugimoto K, Tai Y, Hando T, Tokuda M. Inverse expression of Cdk4 and p16 in epithelial ovarian tumors. Gynecol Oncol 2000;79:230-7.
14. Raspollini MR, Amunni G, Villanucci A, Baroni G, Taddei GL. P16INK4a overexpression is associated with poor clinical outcome in ovarian carcinoma. J Chemother 2004;16:411-3.
15. Kommoss S, du Bois A, Ridder R, Trunk MJ, Schmidt D, Pfisterer J, Kommoss F. The AGO-OVAR Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Br J Cancer 2007;96:306-13.
16. Tisserand P, Fouquet C, Marck V, Mallard C, Fabre M, Vielh P, Soussi T. Thinprep-processed fine-needle samples of breast are effective material for RNA- and DNA-based molecular diagnosis. Application to p53 mutation analysis. Cancer 2003;99:223-32.
17. Piaton E, Faÿnel J, Ruffion a, Lopez JG, Perrin P, Devonec M. p53 immunodetection of liquid-based processed urinary samples helps to identify bladder tumours with a higher risk of progression. Br J Cancer 2005;93:242-7.
18. Kikuchi Y, Miyauchi M, Kizawa I, Oomori K, Katoh K. Establishment of a cisplatin-resistant human ovarian cancer cell line. J Natl Cancer Inst 1986;77:1181-5.
19. Yamamoto K, Kikuchi Y, Kudoh K, Hirata J, Kita T, Nagata I. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selected for cisplatin-resistant ovarian carcinoma. Jpn J Clin Oncol 2000;30:446-9.
20. Kudoh K, Ichikawa Y, Yoshida S, Hirai M, Kikuchi Y, Nagata I, Miwa M, Uchida K. Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer. Int J Cancer 2002;99:579-82.
21. Milde-Langosch K, Hagen M, Bamberger AM, Löning T. Expression and prognostic value of the cell-cycle regulatory proteins. Rb, p16MTS1, p21WAF1, p27KIP1, cyclin. E, and cyclin. D2, in ovarian cancer. Int J Gynecol Pathol 2003;22:168-74.
22. O'Neill CJ, McBride HA, Connolly LE, Deavers MT, Malpica A, McCluggage WG. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology 2007;50:773-9.
23. Milde-Langosch K, Ocon E, Becker G, Löning T. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int J Cancer 1998;79:61-5.
24. Zhao P, Mao X, Talbot IC. Aberrant cytological localization of p16 and CDK4 in colorectal epithelia in the normal adenoma carcinoma sequence. World J Gastroenterol 2006;12:6391-6.
25. Shiozawa T, Nikaido T, Shimizu M, Zhai Y, Fujii S. Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma. Cancer 1997;80:2250-6.
26. Nilsson K, Landberg G. Subcellular localization, modification and protein complex formation of the cdk-inhibitor p16 in Rb-functional and Rb-inactivated tumor cells. Int J Cancer 2006;118:1120-5.
27. Bedrossian CW. Special stains, the old and the new: the impact of immunocytochemistry in effusion cytology. Diagn Cytopathol 1998;18:141-9.
28. Wright RG, Halford JA. Evaluation of thin-layer methods in urine cytology. Cytopathology 2001;12:306-13.
29. Piaton E, Hutin K, Faÿnel J, Ranchin MC, Cottier M. Cost efficiency analysis of modern cytocentrifugation methods versus liquid based (Cytyc Thinprep) processing of urinary samples. J Clin Pathol 2004;57:1208-12.
30. Leung SW, Bédard YC. Immunocytochemical staining on ThinPrep processed smears. Mod Pathol 1996;9:304-6.
31. Mensch LS, Weller L, Simmons-Arnold L, Gibson PC, Leiman G, Beatty B. GLUT1 antibody staining in thin-layer specimens of benign and malignant body cavity effusions. Acta Cytol 2002;46:813-8.